Pemetrexed was shown to only be effective in non-squamous cell carcinoma. Similarly, the impact of histology to treatment was also seen with pemetrexed. In 2004, a randomized phase II trial comparing chemotherapy versus bevacizumab plus chemotherapy reported results that showed that NSCLC patients with non-squamous type responded better to bevacizumab with chemotherapy. The trial demonstrated no difference in overall survival among the different treatment regimens. In 2002, the Eastern Cooperative Oncology Group published results of a randomized phase III trial comparing four platinum-based doublets in first-line metastatic NSCLC. Research examining the treatment benefits of chemotherapy has plateaued. For decades, multiple trials have compared different chemotherapy regimens and resulted in marginal improvements in the OS. For patients that receive supportive care in conjunction with induction platinum-based chemotherapy, historically, the median OS has been 8–12 months. Median overall survival (OS) for metastatic NSCLC patients is about 4–5 months with supportive care alone. Advanced NSCLC includes those who present with metastatic disease or recur following initial definitive treatment. Finally, non-small cell lung cancer (NSCLC) comprised about 85% of the newly diagnosed lung cancer cases. This dismal outcome in lung cancers is due, in part to the fact that more than half of the patients, about 55%, presented with metastatic lung cancer at the time of diagnosis. The total number of deaths attributed to lung cancer is greater than from colon, prostate, and breast cancer combined. It is estimated that in 2020 there will be 228,820 newly diagnosed cases of lung cancer and 135,720 deaths attributed to lung cancer. Lung cancer is the most common cause of cancer-related death and the second most common malignancy reported in the USA and worldwide. Finally, we present a brief review of the emerging agents and ongoing clinical studies. Advances are divided into (1) targeted agents, (2) antibody-drug conjugates, and (3) immunotherapies. These drugs either offer better alternatives to current standard drugs in the same class or are a completely new class of drugs with novel mechanisms of action. In this review, we summarize the recent advances in advanced/metastatic NSCLC therapeutics with a specific focus on first in-human or early-phase I/II clinical trials. The new medications provide promising efficacy and safety resulting in improved long-term survival for a significant number of patients. Molecular and immunogenic testing makes personalized medicine possible for patients with advanced NSCLC. In the last 10 years, the US Food and Drug Administration (FDA) has approved more than 17 new medications for this devastating disease and more are coming. Recent advances in targeted therapy and immunotherapy have changed the landscape for the treatment of advanced NSCLC. Survival time is often short because of limited treatment options. Artwork can be extracted or resized either in a batch or individually.ġ2.Advanced non-small cell lung cancer (NSCLC) is the most common type of lung cancer, with a poor prognosis and no known cure. Batch Editing - Edit multiple files at once quickly and easily.ġ1. Online Sources - Search for tags on MusicBrainz and album artwork on Google.ġ0. Functions - Metadatics has a number of built in function to quickly manipulate data.ĩ. Metadatics provides all you need to edit metadata with ease and flexibility.Ĩ. Metadatics is a powerful and advanced audio metadata editor.ħ. It supports batch editing of most common audio file types including MP3, M4A, AIFF, WAV, FLAC, APE, OGG, WMA, and more.Ħ. File Rename - Generate directory structures and rename files based on metadata.ĥ. Album Artwork - Metadatics supports reading and writing multiple images per file.Ĥ. Lookup metadata from online sources, rename files based on metadata, or manipulate metadata using one of the many built in functions.ģ. Support For Many Metadata Formats - Metadatics supports reading and writing ID3v1, ID3v2, MP4, Vorbis, APE, and ASF tags all from a variety of audio file types.Ģ.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |